AnaptysBio stock zoomed higher Wednesday after announcing a $100 million offering that includes participation from pharma ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB) to $52 from $36 and keeps a Buy rating on the shares following the company’s Q4 ...

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on AnaptysBio (ANAB) to $22 from $19 and keeps a Neutral rating on the shares after the company announced Phase 2b topline ...

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in ...

Truist notes that AnaptysBio (ANAB) reported the “much anticipated” results of its Phase 2b trial of rosnilimab for moderate-to-severe rheumatoid arthritis and that the primary endpoint of DAS ...

Ratings for AnaptysBio (NASDAQ:ANAB) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table ...

Reports Q4 revenue $43.11M, consensus $7.79M. The increase in non-cash revenue in 2024 is due to $15M and $25M commercial milestones earned for ...

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush issued their FY2029 earnings estimates for AnaptysBio in a research report issued to clients and investors ...

Has AnaptysBio, Inc. (ANAB) been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.